Trump Admin Secures Makes Another Big Move to Cut Drug Costs

President Donald J. Trump notched another win in his push to rein in soaring prescription drug costs, announcing a new agreement with Regeneron Pharmaceuticals aimed at delivering lower prices for American patients—particularly those relying on government healthcare programs.

The deal, unveiled during a White House event, brings Regeneron in line with a group of 17 major drug manufacturers targeted by the administration’s “most favored nation” pricing initiative. The policy is designed to end the long-standing disparity where Americans often pay far more for medications than patients in other developed nations.

Under the agreement, Regeneron will reduce prices on certain drugs sold through Medicaid and expand discounts on select treatments. Among the most notable changes is a significant price cut for the company’s cholesterol drug Praluent, which will now be offered for $225 through a government-linked platform—a fraction of typical U.S. costs.

Administration officials framed the deal as a major step toward broader reform. White House health adviser Chris Klomp noted that agreements secured so far now cover roughly 86% of the branded pharmaceutical market, with plans to expand negotiations to smaller biotech firms in the near future.

At the heart of the initiative is a simple principle: Americans should not be subsidizing lower drug prices abroad. The “most favored nation” model aims to tie U.S. pricing more closely to international benchmarks, leveraging federal policy tools to force long-overdue changes in the pharmaceutical industry.

To get results, the administration has not hesitated to apply pressure—utilizing tariff threats, regulatory incentives, and a renewed emphasis on domestic manufacturing to bring companies to the table. Supporters argue this strategy reflects a pro-market approach that prioritizes both affordability and American industry strength.

Critics, however, note that many of the immediate savings are concentrated within Medicaid, which already benefits from statutory discounts. That means the short-term financial impact for the broader public may be limited.

Still, backers of the plan say it lays the groundwork for more sweeping reforms. By establishing precedent and securing buy-in from major players, the administration is positioning itself to expand these pricing models across additional programs and private markets.

In a parallel development, Regeneron also announced a major medical breakthrough: approval from the Food and Drug Administration for a gene therapy targeting a rare form of inherited hearing loss caused by otoferlin-related deafness.

The treatment represents a cutting-edge advancement in biotechnology—one that could restore hearing in children affected by the condition. In a notable move, the company says it will provide the therapy at no cost to eligible patients, despite gene therapies often carrying price tags in the hundreds of thousands—or even millions—of dollars.

Together, the announcements highlight the ongoing challenge facing policymakers: how to encourage life-saving innovation while ensuring treatments remain accessible and affordable for everyday Americans.

As the administration continues its aggressive push on drug pricing, the broader impact will depend on whether these early agreements expand beyond Medicaid and translate into meaningful savings across the healthcare system.

With midterm elections on the horizon, the issue is likely to remain front and center—offering a clear contrast in how each party approaches one of the most pressing economic concerns facing American families.